Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NEAT1_2 antisense oligonucleotide
- Development stage
- Preclinical
- Lead developer
- University of Kansas Medical Center
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
NEAT1_2 antisense oligonucleotide (NEAT1_2 ASO) is a target-specific RNA-targeted therapeutic designed to knock down the expression of the long non-coding RNA (lncRNA) isoform NEAT1_2. NEAT1_2 is a critical structural scaffold required for the assembly of nuclear paraspeckles, which are membrane-less nuclear bodies that sequester double-stranded RNA (dsRNA) and microRNAs to promote tumor progression and suppress anti-tumor immune responses. By utilizing antisense oligonucleotide technology to target and degrade NEAT1_2, researchers aim to disrupt paraspeckle formation, restore interferon-alpha (IFNα) signaling, and induce anti-tumor immunity. This approach is being investigated preclinically for the prevention of invasive and metastatic progression in ductal carcinoma in situ (DCIS) and other malignancies.
- Other names
- NEAT1_2 ASONEAT1_2 antisense oligo
02
Targets
NEAT1 (Nuclear paraspeckle assembly transcript 1)
Beyond the preview
Go deeper on NEAT1_2 antisense oligonucleotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NEAT1_2 antisense oligonucleotide.